Janux Therapeutics price target lowered to $100 from $150 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on Janux Therapeutics (JANX) to $100 from $150 and keeps an Overweight rating on the shares. Janux reported Q4 results and outlined 2026 guidance for clinical updates across its TRACTr and ARM platforms, emphasizing continued execution, the analyst tells investors in a research note. Management improved its narrative, clarifying data presentation amid intensifying competitive dynamics, especially from China, the firm says.